1. Home
  2. GPRK vs CELC Comparison

GPRK vs CELC Comparison

Compare GPRK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPRK
    SELLHOLDBUYas of 11 hours ago
  • CELC
    SELLHOLDBUYas of 11 hours ago
  • Stock Information
  • Founded
  • GPRK 2002
  • CELC 2011
  • Country
  • GPRK Colombia
  • CELC United States
  • Employees
  • GPRK N/A
  • CELC N/A
  • Industry
  • GPRK Oil & Gas Production
  • CELC Medical Specialities
  • Sector
  • GPRK Energy
  • CELC Health Care
  • Exchange
  • GPRK Nasdaq
  • CELC Nasdaq
  • Market Cap
  • GPRK 468.4M
  • CELC 489.7M
  • IPO Year
  • GPRK N/A
  • CELC 2017
  • Fundamental
  • Price
  • GPRK $10.54
  • CELC $13.62
  • Analyst Decision
  • GPRK Strong Buy
  • CELC Strong Buy
  • Analyst Count
  • GPRK 2
  • CELC 6
  • Target Price
  • GPRK $12.50
  • CELC $29.17
  • AVG Volume (30 Days)
  • GPRK 590.7K
  • CELC 285.5K
  • Earning Date
  • GPRK 11-06-2024
  • CELC 11-14-2024
  • Dividend Yield
  • GPRK 4.08%
  • CELC N/A
  • EPS Growth
  • GPRK N/A
  • CELC N/A
  • EPS
  • GPRK 1.97
  • CELC N/A
  • Revenue
  • GPRK $716,838,000.00
  • CELC N/A
  • Revenue This Year
  • GPRK N/A
  • CELC N/A
  • Revenue Next Year
  • GPRK $22.01
  • CELC N/A
  • P/E Ratio
  • GPRK $5.15
  • CELC N/A
  • Revenue Growth
  • GPRK N/A
  • CELC N/A
  • 52 Week Low
  • GPRK $7.24
  • CELC $11.51
  • 52 Week High
  • GPRK $11.72
  • CELC $22.19
  • Technical
  • Relative Strength Index (RSI)
  • GPRK 62.26
  • CELC 56.70
  • Support Level
  • GPRK $8.50
  • CELC $12.53
  • Resistance Level
  • GPRK $11.45
  • CELC $13.91
  • Average True Range (ATR)
  • GPRK 0.46
  • CELC 0.76
  • MACD
  • GPRK -0.02
  • CELC 0.18
  • Stochastic Oscillator
  • GPRK 84.65
  • CELC 87.34

Stock Price Comparison Chart: GPRK vs CELC

GPRK
CELC
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202505101520253035GPRK VS CELC

About GPRK Geopark Ltd

GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use